Conditions:  Atypical Teratoid/Rhabdoid Tumor;  Epithelioid Sarcoma;  Kidney Medullary Carcinoma;  Malignant Solid Neoplasm;  Poorly Differentiated Chordoma;  Recurrent Atypical Teratoid/Rhabdoid Tumor;  Recurrent Chordoma;  Recurrent Epithelioid Sarcoma;  Recurrent Kidney Medullary Carcinoma;  Recurrent Rhabdoid Tumor;  Refractory Atypical Teratoid/Rhabdoid Tumor;  Refractory Chordoma;  Refractory Epithelioid Sarcoma;  Refractory Kidney Medullary Carcinoma;  Refractory Rhabdoid Tumor;  Rhabdoid Tumor
Interventions:  Biological: Atezolizumab;  Procedure: Biospecimen Collection;  Procedure: Computed Tomography;  Other: Fludeoxyglucose F-18;  Procedure: Magnetic Resonance Imaging;  Procedure: Positron Emission Tomography;  Biological: Tiragolumab;  Procedure: X-Ray Imaging
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions:  Biological: Atezolizumab;  Procedure: Biospecimen Collection;  Procedure: Computed Tomography;  Other: Fludeoxyglucose F-18;  Procedure: Magnetic Resonance Imaging;  Procedure: Positron Emission Tomography;  Biological: Tiragolumab;  Procedure: X-Ray Imaging
Sponsor:  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
